<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-31T22:10:59Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/11607" metadataPrefix="marc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/11607</identifier><datestamp>2026-05-15T11:45:27Z</datestamp><setSpec>com_10259_4219</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_4220</setSpec></header><metadata><record xmlns="http://www.loc.gov/MARC21/slim" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>00925njm 22002777a 4500</leader>
<datafield tag="042" ind1=" " ind2=" ">
<subfield code="a">dc</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">García Bustillo, Álvaro</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Youn, Jinyoung</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Ahn, Jong Hyeon</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Ojo, Oluwadamilola</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Okubadejo, Njideka</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Aldaajani, Zakiyah</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Essam, Mohamed</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Shalash, Ali</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Cardozo, Adriana</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Spindler, Meredith</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Mari, Zoltan</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="720" ind1=" " ind2=" ">
<subfield code="a">Cubo Delgado, Esther</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield tag="260" ind1=" " ind2=" ">
<subfield code="c">2026-02</subfield>
</datafield>
<datafield tag="520" ind1=" " ind2=" ">
<subfield code="a">Background: Overcoming existing access barriers is crucial for better-specialized health care ofpatients with Parkinson’s disease (PD).ObjectiveObjective: The aim of the study was to compare the access and visit quality/acceptability between in-ofﬁce andvirtual telemedicine visits.MethodsMethods: This was an international, randomized, case-control, prospective, observational study. Patients wererandomly assigned either to the control group (in-person/in-ofﬁce visits at baseline, 3, 6, 9, and 12 months) or tothe study group (in-ofﬁce visits at baseline, 6, and 12 months, and telemedicine visits at 3 and 9 months).Telemedicine visits were conducted using videoconferencing apps that were readily accessible to the patient/caregivers. Outcomes were feasibility, usability, and the noninferiority of telemedicine compared to in-ofﬁcevisits in PD patients regarding clinical progression and initiation of pharmacological/nonpharmacologicaltreatments over 1-year follow-up.ResultsResults: We included 209 PD patients from 6 countries (Nigeria, Spain, Saudi Arabia, South Korea, Egypt, andUruguay), mean age 64.9   12.2 years, 59% males, median Hoehn &amp; Yahr stage 2 (1–4). Overall, diseaseprogression (MDS-Uniﬁed PD rating scale), quality of life (PD-Quality of life 39-items) scores, and therapeuticchanges were similar in both groups. After 1 year, 124 patients 48.3%, (control group) and 52.1% (study group)completed the visits (P = 0.52), with a similar high rate of patient’s satisfaction with the visits (P = 0.57).ConclusionsConclusions: This study represents real-world telemedicine practice in different world regions using atelemedicine approach complementary to in-person visits. Based on these results, feasibility, clinicalmanagement, PD disease progression, and patient’s quality of life are similar when using telemedicine versusin-ofﬁce visits. Future research should explore ways to integrate different healthcare technologies for long-termPD management.</subfield>
</datafield>
<datafield tag="024" ind2=" " ind1="8">
<subfield code="a">2330-1619</subfield>
</datafield>
<datafield tag="024" ind2=" " ind1="8">
<subfield code="a">https://hdl.handle.net/10259/11607</subfield>
</datafield>
<datafield tag="024" ind2=" " ind1="8">
<subfield code="a">10.1002/mdc3.70314</subfield>
</datafield>
<datafield tag="024" ind2=" " ind1="8">
<subfield code="a">2330-1619</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Telemedicine</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Parkinson's disease</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Multidisciplinary team</subfield>
</datafield>
<datafield tag="245" ind1="0" ind2="0">
<subfield code="a">The Feasibility and Practical Utility of Virtual Visits for Patients with Parkinson's Disease in Different World Regions</subfield>
</datafield>
</record></metadata></record></GetRecord></OAI-PMH>